Clinical Trials Arena on MSN2d
Gilead to launch Phase III once-yearly HIV PrEP trial after Phase I success
Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...
BioSpace2d
Gilead, GSK-ViiV Move Ahead With Long-Acting HIV Options Following Early-Stage Readouts
Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...
STAT3d
Gilead data suggest once-yearly shot of PrEP drug blocks HIV infection
Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...
The Business Journals1mon
How key drugs boosted Gilead — and how the Inflation Reduction Act could deliver a billion-dollar hit
The company expects FDA approval this summer of its twice-a-year injectable HIV prevention drug lenacapavir. Gilead Sciences Inc.'s sales exceeded Wall Street expectations last year — thanks in ...
Fierce Pharma3d
A once-yearly PrEP? Gilead's lenacapavir shows promise as company plots phase 3
After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...
Morningstar2d
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
“Gilead is fueling the next wave of innovation in HIV to help end the epidemic globally,” said Jared Baeten, MD, PhD, Senior Vice President, Virology Therapeutic Area Head. “Our ...
Gilead posts early Phase 1 data for once-yearly HIV PrEP therapy
Gilead (GILD) stock in focus as its HIV anti-viral lenacapavir shows promise in HIV prevention with once-yearly PrEP ...
Yahoo Finance2d
Gilead to launch Phase III once-yearly HIV PrEP trial after Phase I success
Gilead Sciences's senior vice president and virology therapeutic area head Dr Jared Baeten said: “Gilead is continuing to innovate in our work to develop additional person-centered long-acting ...